Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovation To Drive Long-Term Survival In China Pharma Market - But What Kind Of Innovation?

This article was originally published in PharmAsia News

Executive Summary

BEIJING - For Big Pharma and domestic players competing in China's market, innovation is essential for long-term survival, even as pricing strategies might help grab market share over the shorter term, according to a prominent analyst who monitors China's healthcare sector

You may also be interested in...



China Should Step Up Funding For Rural Health Facilities, Medical Devices In New Five-Year Plan - EU Chamber Of Commerce In China

BEIJING - China's new Five Year Plan for economic and social development should be amended to provide greater support for upgrading rural hospitals, physician education, and decades-old medical equipment, according to an assessment of the guidelines by the European Union Chamber of Commerce in China

China Should Step Up Funding For Rural Health Facilities, Medical Devices In New Five-Year Plan - EU Chamber Of Commerce In China

BEIJING - China's new Five Year Plan for economic and social development should be amended to provide greater support for upgrading rural hospitals, physician education, and decades-old medical equipment, according to an assessment of the guidelines by the European Union Chamber of Commerce in China

Reimbursement Expansion To Fuel China Pharma Growth In 2011 (Part 1 of 2)

HONG KONG - China's pharmaceutical market is expected to grow around 26% in the coming year with much of the growth fueled by continued implementation of the government's Essential Drug List (EDL) and reimbursement expansion via government insurance plans, said Katherine Lu, senior analyst for China healthcare at Oppenheimer & Co

Related Content

UsernamePublicRestriction

Register

SC077249

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel